Response and toxicity of donor lymphocyte infusions following T cell depleted non-myeloablative allogeneic hematopoietic stem cell transplantation from 3–6/6 HLA matched donors

類似資料

• Feasibility of low dose interleukin-2 therapy following T cell-depleted non-myeloablative allogeneic hematopoietic stem cell transplantation from HLA matched or mismatched family member donors
  著者:: Rizzieri, David A., 等
  出版事項: (2011)
• NATURAL KILLER CELL ENRICHED DONOR LYMPHOCYTE INFUSIONS FROM A 3-6/6 HLA MATCHED FAMILY MEMBER FOLLOWING NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
  著者:: Rizzieri, David A., 等
  出版事項: (2010)
• Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies
  著者:: Kanda, Junya, 等
  出版事項: (2013)
• Immune Recovery in Adult Patients Following Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation
  著者:: Kanda, Junya, 等
  出版事項: (2012)
• Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
  著者:: Green, Michael M. B., 等
  出版事項: (2016)